4//SEC Filing
DENG FENG 4
Accession 0001209191-21-048385
CIK 0001831915other
Filed
Jul 26, 8:00 PM ET
Accepted
Jul 27, 8:57 PM ET
Size
16.2 KB
Accession
0001209191-21-048385
Insider Transaction Report
Form 4
DENG FENG
Director
Transactions
- Conversion
Series C Preferred Stock
2021-07-22−4,168,777→ 0 total(indirect: See footnote)→ Common Stock (4,168,777 underlying) - Conversion
Common Stock
2021-07-22+147,933→ 147,933 total(indirect: See footnote) - Conversion
Common Stock
2021-07-22+4,168,777→ 4,168,777 total(indirect: See footnote) - Conversion
Common Stock
2021-07-22+443,800→ 443,800 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-07-22−147,933→ 0 total(indirect: See footnote)→ Common Stock (147,933 underlying) - Conversion
Series D Preferred Stock
2021-07-22−443,800→ 0 total(indirect: See footnote)→ Common Stock (443,800 underlying)
Footnotes (2)
- [F1]Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
- [F2]Shares held directly by Northern Light Venture Capital V, Ltd. ("NLVC V"). Fund V serves as the nominee for each of Northern Light Venture Fund V, L.P., Northern Light Strategic Fund V, L.P. and Northern Light Partners Fund V, L.P (together, the "NLVC V Funds"). Northern Light Partners V, L.P., a Cayman Islands exempted limited liability partnership, is the general partner of the NLVC V Funds. NLVC V is the general partner of Northern Light Partners V, L.P. Feng Deng is the controlling shareholder of NLVC V and may be deemed to have voting and dispositive power with respect to the shares held by NLVC V.
Documents
Issuer
Cytek Biosciences, Inc.
CIK 0001831915
Entity typeother
Related Parties
1- filerCIK 0001165399
Filing Metadata
- Form type
- 4
- Filed
- Jul 26, 8:00 PM ET
- Accepted
- Jul 27, 8:57 PM ET
- Size
- 16.2 KB